Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Sonic Hedgehog repression underlies gigaxonin mutation–induced motor deficits in giant axonal neuropathy
Yoan Arribat, … , Mireille Rossel, Pascale Bomont
Yoan Arribat, … , Mireille Rossel, Pascale Bomont
Published September 10, 2019
Citation Information: J Clin Invest. 2019;129(12):5312-5326. https://doi.org/10.1172/JCI129788.
View: Text | PDF
Research Article Neuroscience Article has an altmetric score of 20

Sonic Hedgehog repression underlies gigaxonin mutation–induced motor deficits in giant axonal neuropathy

  • Text
  • PDF
Abstract

Growing evidence shows that alterations occurring at early developmental stages contribute to symptoms manifested in adulthood in the setting of neurodegenerative diseases. Here, we studied the molecular mechanisms causing giant axonal neuropathy (GAN), a severe neurodegenerative disease due to loss-of-function of the gigaxonin–E3 ligase. We showed that gigaxonin governs Sonic Hedgehog (Shh) induction, the developmental pathway patterning the dorso-ventral axis of the neural tube and muscles, by controlling the degradation of the Shh-bound Patched receptor. Similar to Shh inhibition, repression of gigaxonin in zebrafish impaired motor neuron specification and somitogenesis and abolished neuromuscular junction formation and locomotion. Shh signaling was impaired in gigaxonin-null zebrafish and was corrected by both pharmacological activation of the Shh pathway and human gigaxonin, pointing to an evolutionary-conserved mechanism regulating Shh signaling. Gigaxonin-dependent inhibition of Shh activation was also demonstrated in primary fibroblasts from patients with GAN and in a Shh activity reporter line depleted in gigaxonin. Our findings establish gigaxonin as a key E3 ligase that positively controls the initiation of Shh transduction, and reveal the causal role of Shh dysfunction in motor deficits, thus highlighting the developmental origin of GAN.

Authors

Yoan Arribat, Karolina S. Mysiak, Léa Lescouzères, Alexia Boizot, Maxime Ruiz, Mireille Rossel, Pascale Bomont

×

Figure 6

Decreased responsiveness of primary fibroblasts from patients with GAN to the activation of the Shh pathway.

Options: View larger image (or click on image) Download as PowerPoint
Decreased responsiveness of primary fibroblasts from patients with GAN t...
(A) Shh-CM treatment for 4 hours causes translocation of Smo into the cilium (arl13b) in control but this is greatly decreased in patient primary fibroblasts, bearing distinct mutations in the GAN gene: GANΔex10-11 and GANA49E. Quantification of the proportion of Smo-positive cilia in control and GAN fibroblasts, with or without Shh treatment, is shown at the bottom. Statistics: proportions of experimental groups were compared with the χ2 test, data represent mean ± SEM; n = 419 (GANWT), n = 410 (GANWT+Shh), n = 179 (GANΔex10-11), n = 135 (GANΔex10-11+Shh), n = 295 (GANA49E), n = 347 (GANA49E+Shh) from 5 independent experiments; **P < 0.01, ****P < 0.0001 correspond to the comparison between patient and control cells in the presence of Shh (pairwise comparisons of patient with control cells are not statistically significant in the absence of Shh). (B) Shh-CM treatment for 24 hours increases the length of primary cilia in control but not in GANΔex10-11 and GANA49E patient primary fibroblasts. Quantification of the ciliary length in human fibroblasts, showing a significant increase upon Shh-CM stimulation in control but not in mutant cells, is shown at the bottom. Statistics: with normality of the distribution of the data, a 1-way ANOVA test (with Bonferroni’s post hoc test) was used, mean ± SEM; n = 24 (GANWT), n = 26 (GANWT+Shh), n = 19 (GANΔex10-11), n = 28 (GANΔex10-11+Shh), n = 22 (GANA49E), n = 23 (GANA49E+Shh); NS, not statistically significant; **P < 0.01. Scale bars: 10 μm. Insets: Original magnification ×2.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 24 X users
Referenced in 1 patents
17 readers on Mendeley
See more details